Background The benefit of tocilizumab on mortality and time to recovery in people with severe COVID pneumonia may depend on appropriate timing. The objective was to estimate the impact of tocilizumab administration on switching respiratory support states, mortality and time to recovery. Methods In an observational study, a continuous-time Markov multi-state model was used to describe the sequence of respiratory support states including: no respiratory support (NRS), oxygen therapy (OT), non-invasive ventilation (NIV) or invasive mechanical ventilation (IMV), OT in recovery, NRS in recovery. Results Two hundred seventy-one consecutive adult patients were included in the analyses contributing to 695 transitions across states. The prevalence o...
Introduction The aim of this study was to determine the efficacy of early tocilizumab treatment for ...
International audienceTocilizumab, an anti-interleukin-6 receptor, administrated during the right ti...
BackgroundThe aim of this secondary analysis of the TESEO cohort is to identify, early in the course...
Background The benefit of tocilizumab on mortality and time to recovery in people with severe COVID ...
BackgroundThe benefit of tocilizumab on mortality and time to recovery in people with severe COVID p...
Background: Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathog...
International audienceImportance Severe pneumonia with hyperinflammation and elevated interleukin-6...
Importance: The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of people world...
Background: The severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection i...
Background: Pneumonia with respiratory failure represents the main cause of death in COVID-19, where...
Introduction The aim of this study was to determine the efficacy of early tocilizumab treatment for ...
International audienceTocilizumab, an anti-interleukin-6 receptor, administrated during the right ti...
BackgroundThe aim of this secondary analysis of the TESEO cohort is to identify, early in the course...
Background The benefit of tocilizumab on mortality and time to recovery in people with severe COVID ...
BackgroundThe benefit of tocilizumab on mortality and time to recovery in people with severe COVID p...
Background: Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathog...
International audienceImportance Severe pneumonia with hyperinflammation and elevated interleukin-6...
Importance: The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of people world...
Background: The severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection i...
Background: Pneumonia with respiratory failure represents the main cause of death in COVID-19, where...
Introduction The aim of this study was to determine the efficacy of early tocilizumab treatment for ...
International audienceTocilizumab, an anti-interleukin-6 receptor, administrated during the right ti...
BackgroundThe aim of this secondary analysis of the TESEO cohort is to identify, early in the course...